{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:10:19Z","timestamp":1791414619870,"version":"4.3.3"},"reference-count":137,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.3816\/ccc.2006.n.047","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:06:03Z","timestamp":1221080763000},"page":"288-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Profiling Dihydropyrimidine Dehydrogenase Deficiency in Patients with Cancer Undergoing 5-Fluorouracil\/Capecitabine Therapy"],"prefix":"10.3816","volume":"6","author":[{"given":"C\u00e9dric","family":"Mercier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Ciccolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CCC.2006.n.047_bib1","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/1097-0142(19911101)68:9<1903::AID-CNCR2820680910>3.0.CO;2-9","article-title":"A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa","volume":"68","author":"Peters","year":"1991","journal-title":"Cancer"},{"key":"10.3816\/CCC.2006.n.047_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0277-5379(91)90512-C","article-title":"Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: enzyme activity and inhibition by 5-fluoro-2\u2032-deoxy-uridine-5\u2032-monophosphate","volume":"27","author":"Peters","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.3816\/CCC.2006.n.047_bib3","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1054\/bjoc.2001.1833","article-title":"Fluoropyrimidine sensitivity of human MCF-7 breast cancer cells stably transfected with human uridine phosphorylase","volume":"84","author":"Cuq","year":"2001","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2006.n.047_bib4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1358\/dot.2004.40.5.850491","article-title":"Uridine phosophorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation","volume":"40","author":"Cao","year":"2004","journal-title":"Drugs Today (Barc)"},{"key":"10.3816\/CCC.2006.n.047_bib5","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/sj.bjc.6690589","article-title":"Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase","volume":"80","author":"Evrard","year":"1999","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2006.n.047_bib6","first-page":"1529","article-title":"Enhanced antitumor activity of 5-fluorouracil in combination with 2\u2032-deoxyinosine in human colorectal cell lines and human colon tumor xenografts","volume":"6","author":"Ciccolini","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1472-8206.2000.tb00403.x","article-title":"Monitoring of the intracellular activation of 5-fluorouracil to deoxyribonucleotides in HT29 human colon cell line: application to modulation of metabolism and cytotoxicity study","volume":"14","author":"Ciccolini","year":"2000","journal-title":"Fundam Clin Pharmacol"},{"key":"10.3816\/CCC.2006.n.047_bib8","first-page":"133","article-title":"Combination of thymidine phosphorylase gene transfer and deoxyinosine treatment greatly enhances 5-fluorouracil antitumor activity in vitro and in vivo","volume":"1","author":"Ciccolini","year":"2001","journal-title":"Mol Cancer Ther"},{"key":"10.3816\/CCC.2006.n.047_bib9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.cad.0000198914.83195.61","article-title":"Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: an in-vitro study","volume":"17","author":"Fanciullino","year":"2006","journal-title":"Anticancer Drugs"},{"key":"10.3816\/CCC.2006.n.047_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/1568011043482089","article-title":"Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story","volume":"4","author":"Ciccolini","year":"2004","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"10.3816\/CCC.2006.n.047_bib11","doi-asserted-by":"crossref","first-page":"8171","DOI":"10.1016\/S0021-9258(18)34313-8","article-title":"Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography","volume":"257","author":"Sommadossi","year":"1982","journal-title":"J Biol Chem"},{"key":"10.3816\/CCC.2006.n.047_bib12","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/0006-2952(84)90688-9","article-title":"A mathematical model of the kinetics of 5-fluorouracil and its catabolites in freshly isolated rat hepatocytes","volume":"33","author":"Mentre","year":"1984","journal-title":"Biochem Pharmacol"},{"key":"10.3816\/CCC.2006.n.047_bib13","doi-asserted-by":"crossref","first-page":"17102","DOI":"10.1016\/S0021-9258(18)41899-6","article-title":"Purification and characterization of dihydropyrimidine dehydrogenase from human liver","volume":"267","author":"Lu","year":"1992","journal-title":"J Biol Chem"},{"key":"10.3816\/CCC.2006.n.047_bib14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/bms.1200090806","article-title":"Quantitative analysis of 5-fluorouracil and 5,6-dihydrofluorouracil in plasma by gas chromatography mass spectrometry","volume":"9","author":"Aubert","year":"1982","journal-title":"Biomed Mass Spectrom"},{"key":"10.3816\/CCC.2006.n.047_bib15","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"Etienne","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.047_bib16","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1200\/JCO.1992.10.7.1171","article-title":"Influence of sex and age on fluorouracil clearance","volume":"10","author":"Milano","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.047_bib17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F","article-title":"Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome","volume":"68","author":"Harris","year":"1991","journal-title":"Cancer"},{"key":"10.3816\/CCC.2006.n.047_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002800050635","article-title":"Inter-and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells","volume":"40","author":"Grem","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CCC.2006.n.047_bib19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1349-7006.2001.tb01100.x","article-title":"Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-fluorouracil","volume":"92","author":"Yamaguchi","year":"2001","journal-title":"Jpn J Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/00007691-199904000-00002","article-title":"Dihydropyrimidine dehydrogenase activity in a Korean population","volume":"21","author":"Sohn","year":"1999","journal-title":"Ther Drug Monit"},{"key":"10.3816\/CCC.2006.n.047_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2125.1998.00751.x","article-title":"Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects","volume":"46","author":"Ridge","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.3816\/CCC.2006.n.047_bib22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2125.2000.00242.x","article-title":"Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations","volume":"50","author":"Morsman","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.3816\/CCC.2006.n.047_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000469002","article-title":"Dihydropyrimidine dehydrogenase activity in human blood mononuclear cells","volume":"42","author":"Tuchman","year":"1989","journal-title":"Enzyme"},{"key":"10.3816\/CCC.2006.n.047_bib24","first-page":"2899","article-title":"Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients","volume":"52","author":"Fleming","year":"1992","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib25","first-page":"740","article-title":"Dihydropyrimidine dehydrogenase activity in cancer patients","volume":"29A","author":"Fleming","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.3816\/CCC.2006.n.047_bib26","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","article-title":"Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil","volume":"40","author":"van Kuilenburg","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.3816\/CCC.2006.n.047_bib27","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1158\/1078-0432.CCR-05-1520","article-title":"Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients","volume":"11","author":"Ezzeldin","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib28","first-page":"429","article-title":"Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells, and induces high sensitivity to 5-FU treatment","volume":"29","author":"Sato","year":"2006","journal-title":"Int J Oncol"},{"key":"10.3816\/CCC.2006.n.047_bib29","doi-asserted-by":"crossref","first-page":"136s","DOI":"10.1200\/jco.2005.23.16_suppl.2004","article-title":"Evidence for increased incidence of dihydropyrimidine dehydrogenase (DPD) deficiency in African Americans compared to Caucasians","volume":"23","author":"Mattison","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.047_bib30","first-page":"270","article-title":"Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs","volume":"25","author":"Okuda","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.3816\/CCC.2006.n.047_bib31","first-page":"4663","article-title":"Up-regulation in dihydropyrimidine dehydrogenase activity by raltitrexed causes antagonism in combination with 5-fluorouracil","volume":"23","author":"Nozoe","year":"2003","journal-title":"Anticancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib32","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s10545-005-4218-0","article-title":"Dihydropyrimidine dehydrogenase deficiency presenting at birth","volume":"28","author":"Al Sanna'a","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.3816\/CCC.2006.n.047_bib33","doi-asserted-by":"crossref","first-page":"23192","DOI":"10.1016\/S0021-9258(17)31638-1","article-title":"cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria","volume":"269","author":"Yokota","year":"1994","journal-title":"J Biol Chem"},{"key":"10.3816\/CCC.2006.n.047_bib34","first-page":"1660","article-title":"Structural organization of the human dihydropyrimidine dehydrogenase gene","volume":"57","author":"Johnson","year":"1997","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1258\/000456303321016150","article-title":"Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency","volume":"40","author":"van Kuilenburg","year":"2003","journal-title":"Ann Clin Biochem"},{"key":"10.3816\/CCC.2006.n.047_bib36","first-page":"233","article-title":"Sequence analysis of the 5\u2032-flanking regions of human dihydropyrimidine dehydrogenase gene: identification of a new polymorphism related with effects of 5-fluorouracil","volume":"24","author":"Hasegawa","year":"2005","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.3816\/CCC.2006.n.047_bib37","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/bjc.1998.79","article-title":"Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer","volume":"77","author":"Ridge","year":"1998","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2006.n.047_bib38","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/bjc.1998.73","article-title":"Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours","volume":"77","author":"McLeod","year":"1998","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2006.n.047_bib39","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00003088-200039050-00001","article-title":"Pharmacogenetics: a tool for individualizing antineoplastic therapy","volume":"39","author":"Innocenti","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.3816\/CCC.2006.n.047_bib40","first-page":"1947","article-title":"Dihydropyrimidine dehydrogenase activity: prognostic partner of 5-fluorouracil?","volume":"5","author":"Allegra","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib41","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1172\/JCI118830","article-title":"Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity","volume":"98","author":"Wei","year":"1996","journal-title":"J Clin Invest"},{"key":"10.3816\/CCC.2006.n.047_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00008711","article-title":"Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency","volume":"104","author":"van Kuilenburg","year":"1999","journal-title":"Hum Genet"},{"key":"10.3816\/CCC.2006.n.047_bib43","first-page":"768","article-title":"Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype","volume":"8","author":"Johnson","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib44","first-page":"325","article-title":"High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism","volume":"22","author":"Gross","year":"2003","journal-title":"Int J Oncol"},{"key":"10.3816\/CCC.2006.n.047_bib45","first-page":"2999","article-title":"Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity","volume":"4","author":"Kouwaki","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib46","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00280-003-0749-y","article-title":"Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population","volume":"53","author":"Hsiao","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CCC.2006.n.047_bib47","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1158\/1078-0432.CCR-06-0549","article-title":"Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency","volume":"12","author":"Yu","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib48","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s004390050637","article-title":"Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W","volume":"101","author":"Vreken","year":"1997","journal-title":"Hum Genet"},{"key":"10.3816\/CCC.2006.n.047_bib49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0009-9120(01)00188-6","article-title":"Rapid detection of a common dihydropyrimidine dehydrogenase mutation associated with 5-fluorouracil toxicity and congenital thymine uraciluria using fluorogenic hybridization probes","volume":"34","author":"Nauck","year":"2001","journal-title":"Clin Biochem"},{"key":"10.3816\/CCC.2006.n.047_bib50","first-page":"2566","article-title":"Regulation of dihydropyrimidine dehydrogenase in colorectal cancer","volume":"5","author":"Johnston","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib51","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/abio.1999.4461","article-title":"Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction","volume":"278","author":"Johnson","year":"2000","journal-title":"Ann Biochem"},{"key":"10.3816\/CCC.2006.n.047_bib52","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/109065703322146777","article-title":"Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing highperformance liquid chromatography","volume":"7","author":"Fischer","year":"2003","journal-title":"Genet Test"},{"key":"10.3816\/CCC.2006.n.047_bib53","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/abio.2002.5666","article-title":"A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency","volume":"306","author":"Ezzeldin","year":"2002","journal-title":"Ann Biochem"},{"key":"10.3816\/CCC.2006.n.047_bib54","first-page":"1149","article-title":"Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency","volume":"7","author":"van Kuilenburg","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib55","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1081\/CNV-120001178","article-title":"Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients","volume":"20","author":"Celik","year":"2002","journal-title":"Cancer Invest"},{"key":"10.3816\/CCC.2006.n.047_bib56","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00008571-200004000-00002","article-title":"Known variant DPYD alleles do not explain DPD deficiency in cancer patients","volume":"10","author":"Collie-Duguid","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.3816\/CCC.2006.n.047_bib57","first-page":"507","article-title":"Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver","volume":"2","author":"Chazal","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib58","first-page":"2295","article-title":"Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review)","volume":"14","author":"Milano","year":"1994","journal-title":"Anticancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib59","first-page":"5405","article-title":"Enzymes of uracil catabolism in normal and neoplastic human tissues","volume":"45","author":"Naguib","year":"1985","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/clinchem\/46.1.9","article-title":"Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency","volume":"46","author":"van Kuilenburg","year":"2000","journal-title":"Clin Chem"},{"key":"10.3816\/CCC.2006.n.047_bib61","first-page":"5433","article-title":"Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy","volume":"53","author":"Lu","year":"1993","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib62","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00280-002-0526-3","article-title":"Correlation between clinicopathologic factors and kinetics of metabolic enzymes for 5-fluorouracil given to patients with colon carcinoma by two different dosage regimens","volume":"51","author":"Katsumata","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CCC.2006.n.047_bib63","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.bjc.6690098","article-title":"Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity","volume":"79","author":"Milano","year":"1999","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2006.n.047_bib64","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/01.ftd.0000245771.82720.c7","article-title":"A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy","volume":"28","author":"Ciccolini","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.3816\/CCC.2006.n.047_bib65","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1054\/bjoc.2000.1664","article-title":"5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer","volume":"84","author":"Jodrell","year":"2001","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2006.n.047_bib66","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1067\/mcp.2000.109352","article-title":"Dose and time dependencies of 5-fluorouracil pharmacokinetics","volume":"68","author":"Terret","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.3816\/CCC.2006.n.047_bib67","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000226942","article-title":"Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance","volume":"48","author":"Port","year":"1991","journal-title":"Oncology"},{"key":"10.3816\/CCC.2006.n.047_bib68","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/0009-9236(95)90171-X","article-title":"Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolite enzyme in 5-fluorouracil chemotherapy","volume":"58","author":"Lu","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.3816\/CCC.2006.n.047_bib69","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/annonc\/mdg302","article-title":"Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction","volume":"14","author":"Fleming","year":"2003","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2006.n.047_bib70","first-page":"4705","article-title":"Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene","volume":"6","author":"van Kuilenburg","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib71","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bjc.1989.59","article-title":"5-FU therapeutic monitoring with dose adjustement leads to an improved therapeutic index in head and neck cancer","volume":"59","author":"Santini","year":"1989","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2006.n.047_bib72","first-page":"23","article-title":"The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology","volume":"12","author":"Diasio","year":"1998","journal-title":"Oncology (Williston Park)"},{"key":"10.3816\/CCC.2006.n.047_bib73","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00280-002-0535-2","article-title":"Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics","volume":"51","author":"Maring","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CCC.2006.n.047_bib74","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/bjc.1992.335","article-title":"No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion","volume":"66","author":"Fleming","year":"1992","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2006.n.047_bib75","first-page":"2203","article-title":"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile","volume":"47","author":"Heggie","year":"1987","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib76","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1172\/JCI113308","article-title":"Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity","volume":"81","author":"Diasio","year":"1988","journal-title":"J Clin Invest"},{"key":"10.3816\/CCC.2006.n.047_bib77","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00228-002-0534-6","article-title":"Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report","volume":"58","author":"Bocci","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"10.3816\/CCC.2006.n.047_bib78","first-page":"942","article-title":"Implication of DPD deficiency in severe or lethal toxicities after 5-fluorouracil and capecitabine-based chemotherapies","volume":"46","author":"Ciccolini","year":"2005","journal-title":"Proc Assoc Amer Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib79","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1023\/A:1010939329562","article-title":"A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU","volume":"18","author":"Tsukamoto","year":"2001","journal-title":"Pharm Res"},{"key":"10.3816\/CCC.2006.n.047_bib80","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s00280-005-0139-8","article-title":"Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency","volume":"58","author":"Ciccolini","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CCC.2006.n.047_bib81","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00008571-200210000-00007","article-title":"High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity","volume":"12","author":"van Kuilenburg","year":"2002","journal-title":"Pharmacogenetics"},{"issue":"18 suppl","key":"10.3816\/CCC.2006.n.047_bib82","first-page":"84s","article-title":"Determination of uracil\/UH2 ratio as potential surrogate for DPD status in cancer patients presenting with severe toxicities during fluoropyrimidine treatment","volume":"24","author":"Mercier","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.047_bib83","first-page":"2006","article-title":"Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil","volume":"5","author":"Johnson","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib84","first-page":"3021","article-title":"Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity","volume":"9","author":"Ezzeldin","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib85","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0022-3565(24)37858-9","article-title":"A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs","volume":"287","author":"Okuda","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3816\/CCC.2006.n.047_bib86","first-page":"2832","article-title":"Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5\u2032-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls","volume":"7","author":"Raida","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib87","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3109\/07357909309024846","article-title":"Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity","volume":"11","author":"Lyss","year":"1993","journal-title":"Cancer Invest"},{"issue":"16 suppl","key":"10.3816\/CCC.2006.n.047_bib88","first-page":"135s","article-title":"Prospective study of dihydropyrimidine dehydrogenase (DPD) activity and DPYD IVS14+1G>A mutation in patients developing FU-related toxicities: an updated analysis based on ten-year recruitment across multiple French institutions","volume":"23","author":"Magne","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.047_bib89","first-page":"626","article-title":"Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency","volume":"148","author":"Hooiveld","year":"2004","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.3816\/CCC.2006.n.047_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/dna.1995.14.1","article-title":"Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea","volume":"14","author":"Meinsma","year":"1995","journal-title":"DNA Cell Biol"},{"issue":"suppl 2","key":"10.3816\/CCC.2006.n.047_bib91","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF01811484","article-title":"Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism","volume":"8","author":"Wadman","year":"1985","journal-title":"J Inherit Metab Dis"},{"key":"10.3816\/CCC.2006.n.047_bib92","first-page":"130","article-title":"Diagnosis of dihydropyrimidine dehydrogenase deficiency in a neonate with thymine-uraciluria","volume":"9","author":"Au","year":"2003","journal-title":"Hong Kong Med J"},{"key":"10.3816\/CCC.2006.n.047_bib93","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-4347(97)00253-3","article-title":"Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity","volume":"696","author":"Johnson","year":"1997","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.3816\/CCC.2006.n.047_bib94","first-page":"1159","article-title":"Dihydropyrimidine dehydrogenase activity in lymphocytes: predictive factor for 5-fluorouracil clearance","volume":"79","author":"Etienne","year":"1992","journal-title":"Bull Cancer"},{"key":"10.3816\/CCC.2006.n.047_bib95","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/0006-2952(95)00231-N","article-title":"Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytes","volume":"50","author":"Fernandez-Salguero","year":"1995","journal-title":"Biochem Pharmacol"},{"key":"10.3816\/CCC.2006.n.047_bib96","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/01.ftd.0000162016.11148.1b","article-title":"Improved analysis of 5-fluorouracil and 5,6-dihydro-5-fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling","volume":"27","author":"Di Paolo","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.3816\/CCC.2006.n.047_bib97","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0378-4347(01)00359-0","article-title":"High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity","volume":"762","author":"Deporte-Fety","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.3816\/CCC.2006.n.047_bib98","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00280-005-0174-5","article-title":"Dihydropyrimidine dehydrogenase deficiency in an Indian population","volume":"58","author":"Saif","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CCC.2006.n.047_bib99","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00008571-199412000-00002","article-title":"Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy","volume":"4","author":"Milano","year":"1994","journal-title":"Pharmacogenetics"},{"key":"10.3816\/CCC.2006.n.047_bib100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00007691-199608000-00004","article-title":"Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits","volume":"18","author":"Milano","year":"1996","journal-title":"Ther Drug Monit"},{"key":"10.3816\/CCC.2006.n.047_bib101","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0378-4347(95)00228-B","article-title":"Automated screening system for purine and pyrimidine metabolism disorders using high performance liquid chromatography","volume":"672","author":"Sumi","year":"1995","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.3816\/CCC.2006.n.047_bib102","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1570-0232(03)00044-8","article-title":"Rapid gas chromatographic-mass spectrometric diagnosis of dihydropyrimidine dehydrogenase deficiency and dihydropyrimidinase deficiency","volume":"792","author":"Kuhara","year":"2003","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.3816\/CCC.2006.n.047_bib103","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0378-4347(01)00143-8","article-title":"Simple gas chromatographic-mass spectrometric procedure for diagnosing pyrimidine degradation defects for prevention of severe anticancer side effects","volume":"758","author":"Kuhara","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.3816\/CCC.2006.n.047_bib104","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1570-0232(02)00009-0","article-title":"Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography-tandem mass spectrometry","volume":"769","author":"Jiang","year":"2002","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.3816\/CCC.2006.n.047_bib105","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jchromb.2005.05.044","article-title":"An accurate dihydrouracil\/ uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice","volume":"823","author":"Remaud","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.3816\/CCC.2006.n.047_bib106","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1570-0232(02)00239-8","article-title":"Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity","volume":"774","author":"Garg","year":"2002","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.3816\/CCC.2006.n.047_bib107","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1080\/10826079708000481","article-title":"A simple chromatographic method for the analysis of pyrimidines and their dihydrogenated metabolites","volume":"20","author":"Gamelin","year":"1997","journal-title":"J Liq Chromatogr Relat Technol"},{"key":"10.3816\/CCC.2006.n.047_bib108","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","article-title":"Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage","volume":"17","author":"Gamelin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2006.n.047_bib109","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jchromb.2006.02.046","article-title":"High performance liquid chromatographic assay with UV detection for measurement of dihydrouracil\/ uracil ratio in plasma","volume":"834","author":"Deporte","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.3816\/CCC.2006.n.047_bib110","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2710.2004.00569.x","article-title":"A simple and rapid highperformance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity","volume":"29","author":"Ciccolini","year":"2004","journal-title":"J Clin Pharm Ther"},{"key":"10.3816\/CCC.2006.n.047_bib111","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0378-4347(99)00528-9","article-title":"Measurement of plasma uracil using gas chromatography-mass spectrometry in normal individuals and in patients receiving inhibitors of dihydropyrimidine dehydrogenase","volume":"738","author":"Bi","year":"2000","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.3816\/CCC.2006.n.047_bib112","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jchromb.2006.02.016","article-title":"Liquid chromatographytandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes","volume":"839","author":"Sparidans","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.3816\/CCC.2006.n.047_bib113","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1177\/0091270004268911","article-title":"Important role of the dihydrouracil\/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics","volume":"44","author":"Jiang","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.3816\/CCC.2006.n.047_bib114","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/sj.bjp.0705651","article-title":"Circadian rhythm of dihydrouracil\/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels","volume":"141","author":"Jiang","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.3816\/CCC.2006.n.047_bib115","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1158\/1078-0432.CCR-03-0374","article-title":"Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13Curacil breath test","volume":"10","author":"Mattison","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib116","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1158\/1078-0432.CCR-05-2020","article-title":"The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil","volume":"12","author":"Mattison","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib117","series-title":"DPD Phenotyping in Human Volunteers and a DPD Deficient Patient by Assessing Uracil Pharmacokinetics After an Oral Uracil Test Dose. A Preliminary Report, in \u201cNew Insight of Pyrimidine Antagonists Chemotherapy\u201d","first-page":"102","author":"Maring","year":"2005"},{"key":"10.3816\/CCC.2006.n.047_bib118","first-page":"3032","article-title":"Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients","volume":"6","author":"Bocci","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib119","first-page":"79","article-title":"Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients","volume":"25","author":"Furuhata","year":"2006","journal-title":"J Exp Clin Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib120","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.clpt.2006.06.007","article-title":"A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity","volume":"80","author":"Bocci","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.3816\/CCC.2006.n.047_bib121","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.lungcan.2004.01.015","article-title":"Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer","volume":"45","author":"Shintani","year":"2004","journal-title":"Lung Cancer"},{"key":"10.3816\/CCC.2006.n.047_bib122","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ijc.21843","article-title":"Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response","volume":"119","author":"Matsuyama","year":"2006","journal-title":"Int J Cancer"},{"key":"10.3816\/CCC.2006.n.047_bib123","first-page":"47","article-title":"Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy","volume":"17","author":"Huang","year":"2000","journal-title":"Int J Oncol"},{"key":"10.3816\/CCC.2006.n.047_bib124","first-page":"875","article-title":"Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer","volume":"15","author":"Okumura","year":"2006","journal-title":"Oncol Rep"},{"key":"10.3816\/CCC.2006.n.047_bib125","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1349-7006.1998.tb00509.x","article-title":"Relationship between protein levels and gene expression of dihydropyrimidine dehydrogenase in human tumor cells during growth in culture and in nude mice","volume":"89","author":"Takechi","year":"1998","journal-title":"Jpn J Cancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib126","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1023\/A:1008337913456","article-title":"Characterization of dihydropyrimidine dehydrogenase on immunohistochemistry in colon carcinoma, and correlation between immunohistochemical score and protein level or messenger RNA expression","volume":"11","author":"Takenoue","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2006.n.047_bib127","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s00595-005-3145-x","article-title":"Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression levels in tumor and normal tissue specimens of T3 human colorectal carcinoma","volume":"36","author":"Okita","year":"2006","journal-title":"Surg Today"},{"key":"10.3816\/CCC.2006.n.047_bib128","first-page":"273","article-title":"Immunohistochemical dihydropyrimidine dehydrogenase expression is a good prognostic indicator for patients with Dukes' C colorectal cancer","volume":"24","author":"Oi","year":"2004","journal-title":"Anticancer Res"},{"key":"10.3816\/CCC.2006.n.047_bib129","first-page":"973","article-title":"Establishment of enzyme-linked immunosorbent assays for thymidylate synthase and dihydropyriminide dehydrogenase in cancer tissues","volume":"11","author":"Kurebayashi","year":"2004","journal-title":"Oncol Rep"},{"key":"10.3816\/CCC.2006.n.047_bib130","first-page":"621","article-title":"Dihydropyrimidine dehydrogenase activity of cancerous and non-cancerous tissues in liver and large intestine","volume":"8","author":"Ikeguchi","year":"2001","journal-title":"Oncol Rep"},{"key":"10.3816\/CCC.2006.n.047_bib131","first-page":"177","article-title":"The relationship between survival and the expression of dihydropyrimidine dehydrogenase in patients with colorectal cancer","volume":"16","author":"Hotta","year":"2006","journal-title":"Oncol Rep"},{"key":"10.3816\/CCC.2006.n.047_bib132","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/07357900500524702","article-title":"Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question?","volume":"24","author":"van Kuilenburg","year":"2006","journal-title":"Cancer Invest"},{"key":"10.3816\/CCC.2006.n.047_bib133","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/14622416.3.4.485","article-title":"Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics","volume":"3","author":"Mattison","year":"2002","journal-title":"Pharmacogenomics"},{"key":"10.3816\/CCC.2006.n.047_bib134","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0065-2571(00)00011-X","article-title":"Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil","volume":"41","author":"Johnson","year":"2001","journal-title":"Adv Enzyme Regul"},{"key":"10.3816\/CCC.2006.n.047_bib135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03256180","article-title":"The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil","volume":"21","author":"Gardiner","year":"2002","journal-title":"Adverse Drug React Toxicol Rev"},{"key":"10.3816\/CCC.2006.n.047_bib136","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0090-9556(24)15065-9","article-title":"Prediction of in vivo drugdrug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil","volume":"28","author":"Kanamitsu","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.3816\/CCC.2006.n.047_bib137","first-page":"157","article-title":"Plasma pharmacokinetics of uracil after an oral uracil challenge dose for dihydropyrimidine dehydrogenase (DPD) phenotyping","volume":"23","author":"Maring","year":"2004","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811704753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811704753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:01:34Z","timestamp":1761519694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002811704753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":137,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S1533002811704753"],"URL":"https:\/\/doi.org\/10.3816\/ccc.2006.n.047","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Profiling Dihydropyrimidine Dehydrogenase Deficiency in Patients with Cancer Undergoing 5-Fluorouracil\/Capecitabine Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CCC.2006.n.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}